Dong Won Hwang

Dr. Dong Won Hwang

Seoul National University Hospital, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DHDong Won Hwang
Dong Won Hwang
ELEun Ji Lee
Eun Ji Lee
JCJoo Yeon Chung
Joo Yeon Chung
ELEun Joo Lee
Eun Joo Lee
DKDayoung Kim
Dayoung Kim
OGon behalf of the KoRIA Trial Group
on behalf of the KoRIA Trial Group
Even though rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) has been developed to improve the distribution and penetration depth of anti-cancer agents by pressurized intraperitoneal aerosol chemotherapy (PIPAC), the optimal nozzle position and patient’s posture have not been investigated. Thus, we used nine pigs weighing 50–60 kg, and sprayed 150 mL of 1% methylene blue as an aerosol through the nozzle, DreamPen® (Dreampac Corp., Wonju, Republic of Korea), with a flow rate of 0.6 ml/min under a pressure of 140 to 150 psi for RIPAC in six and three pigs with supine and Trendelenburg positions, respectively. When we evaluated its distribution and penetration depth, even distribution among 13 regions of the abdomen was observed in three pigs with Trendelenburg position regardless of the depth of the nozzle. Regarding penetration depth, the numbers of regions with maximal penetration depth were high in the 2 cm depth of the nozzle with supine position (n = 5) and the 4 cm depth with Trendelenburg position (n = 3). Conclusively, even distribution and maximal penetration of anti-cancer agents can be expected during RIPAC in the medium depth (4 cm) between the nozzle inlet and the visceral peritoneum located on the opposite side of it and the Trendelenburg position.

1 March 2026 in Women's Health Reports
Verified
Journal Article
Open access
YKYounga Kwon
Younga Kwon
HJHye Lim Jung
Hye Lim Jung
HJHwisu Jung
Hwisu Jung
KCKyoung-Chul Chun
Kyoung-Chul Chun
YKYoung Ah Kim
Young Ah Kim
DHDong Won Hwang
Dong Won Hwang
Objective: To evaluate perioperative outcomes and identify predictors of severe postoperative anemia among patients who declined allogeneic blood transfusion and underwent bloodless gynecologic surgery. Methods: We retrospectively analyzed consecutive patients who declined allogeneic blood transfusion and underwent bloodless gynecologic surgery at Inje University Ilsan Paik Hospital between January 2011 and December 2025. Severe postoperative anemia was defined as a postoperative hemoglobin nadir <8.0 g/dL. Univariable and multivariable Firth penalized logistic regression analyses were performed to identify independent predictors. Two multivariable models distinguished preoperative predictors from perioperative explanatory factors. Generalized additive modeling and sensitivity analyses were additionally performed. Results: Among 195 patients, severe postoperative anemia occurred in 18 (9.2%), and only one patient (0.5%) required allogeneic blood transfusion. In the preoperative model, lower preoperative hemoglobin was the only independent predictor of severe postoperative anemia (adjusted OR 0.48, 95% CI 0.33–0.65; P<0.001). In the perioperative model, lower preoperative hemoglobin (adjusted OR 0.46, 95% CI 0.31–0.65; P<0.001) and greater estimated blood loss (adjusted OR 1.38 per 100 mL, 95% CI 1.17–1.69; P<0.001) remained independently associated with severe postoperative anemia. Spline analysis demonstrated a monotonic inverse association between preoperative hemoglobin concentration and postoperative anemia risk. Conclusion: Bloodless gynecologic surgery in patients who declined allogeneic blood transfusion was associated with favorable perioperative outcomes and minimal use of allogeneic transfusion. Preoperative hemoglobin was the strongest and clinically modifiable predictor of severe postoperative anemia, supporting early identification and optimization before surgery.

1 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HJHwisu Jung
Hwisu Jung
HJHye Lim Jung Jung
Hye Lim Jung Jung
YKYounga Kwon
Younga Kwon
KCKyoung-Chul Chun
Kyoung-Chul Chun
YKYoung Ah Kim
Young Ah Kim
DHDong Won Hwang
Dong Won Hwang
Objective: To evaluate the efficacy and safety of immune checkpoint inhibitor (ICI)-based treatments for gynecologic clear cell carcinoma (CCC).Materials and Methods: We performed a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed and Web of Science were searched for studies published between January 2016 and February 2026 that evaluated ICI-based treatments for gynecologic CCC. We included peer-reviewed full-text publications and excluded conference abstracts to ensure mature, verifiable, and consistently reported efficacy and safety data. Eligible studies reported objective response rates (ORR), treatment-related grade ≥3 adverse events, or both. Pooled estimates were calculated using random-effects models, with subgroup analyses by cancer type (ovarian CCC [OCCC]-only vs. mixed gynecologic CCC) and treatment strategy (ICI monotherapy vs. combination therapy).Results: Six studies were analyzed, including 181 patients evaluable for efficacy and 191 for safety. The pooled ORR was 0.32 (95% CI, 0.20–0.45) with substantial heterogeneity (I² = 66.1%). The pooled ORR was numerically lower in OCCC-only studies (0.23; 95% CI, 0.09–0.48) than in mixed cohorts (0.38; 95% CI, 0.23–0.57), although the difference was not statistically significant. The pooled incidence of grade ≥3 adverse events was 0.25 (95% CI, 0.14–0.42; I² = 76.9%) and was higher with combination therapy (31%) than with ICI monotherapy (17%).Conclusions: ICI-based treatments show modest but clinically meaningful antitumor activity in gynecologic CCC, with OCCC demonstrating response rates exceeding the historical benchmarks for unselected ovarian cancer. These findings support the need for further evaluation of immunotherapy in histology-specific and biomarker-driven trials.